中西医结合学院

School of Integrative Medicine.

袁富文 研究员 博导

发布者：中西医发布时间：2026-06-17浏览次数：8237


袁富文，博士，研究员，博士生导师

邮箱：yuanfuwen@shutcm.edu.cn


教育经历

学士  2010.07-2015.07   北京大学（医学学士）

学士  2010.07-2015.07   北京大学（理学学士，双学位）

博士  2015.07-2018.07   北京大学 生物化学与分子生物学 （医学博士，导师：童坦君院士）


工作经历

博士后                                          2018.05-2021.08       Duke University（美国，导师：王前奔教授）

青年研究员，博导 (2024.06-)    2022.01-2024.11       上海中医药大学

研究员，博导                              2024.12-                    上海中医药大学


主要学术兼职

编委/审稿人: Cell Death Differentiation、Science Advances、Advanced Science、Genes & Diseases、Cell Death & Disease、Journal of Urology,、Oncology Letters、Traditional Medicine Research、中华肿瘤防治杂志等。

学术机构：世界中医药联合学会肿瘤精准医学委员会理事/上海药理学会中西医结合药理专委会委员。


背景介绍

袁富文，上海中医药大学研究员、博士生导师，上海市海外高层次人才。毕业于北京大学，获医学学士、心理学学士（双学位）及医学博士学位，随后赴美国杜克大学开展博士后研究。曾荣获美国国防部Early Investigator Research Award、欧洲BIOMOLECULES期刊Young Investigator Award，并入选上海市领军人才（海外）计划。长期致力于肿瘤发生发展及耐药机制研究，综合运用生物信息学、表观遗传学、CRISPR基因编辑及系统组学等前沿技术，结合中西医协同研究策略，系统解析肿瘤恶性进展与耐药形成的关键分子机制，挖掘潜在治疗靶点，并推动肿瘤治疗新技术与候选药物的研发。以第一作者或通讯作者身份在PNAS、Nature Biomedical Engineering、Nucleic Acids Research等国际高水平期刊发表论文20余篇。主编及副主编学术专著2部。获批美国技术专利1项，申请国家发明专利1项。主持国家自然科学基金项目2项、美国国防部基础研究项目1项。开设并主讲研究生课程《系统生物学技术在中医药研究中的应用》，并参编多部行业规划教材。


主持科研及人才项目:

  1. Early Investigator Research Program, 美国国防部，2020.1-2022.1

  2. 上海中医药大学高层次引进人才，2022.1-2026.12

  3. 上海市领军人才（海外），2022.8-2025.8

  4. 国家自然科学基金青年项目，2023.1-2025.12

  5. 国家自然科学基金面上项目，2025.1-2028.12


代表性论文:

  1. Li X, Wang S, Wei Y, Xie C, Chen Y, Wu F, Zhou Q, Song X, Xu X, Xu D, Xu L, Lin L, Yuan F*. AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1. PNAS2026, 123(18):e2534978123

  2. Huang F#, Yuan F#, Li K#, Cui Y#, Li L#, Ye W, Cui Z, Yan J, Chen Q, Nicchitta C, Zhang Y, Hankey W, Everitt J, Huang K, Wang M, Chen M, Huang J, Wang H, Wagner E, Lu X, Dong Y*, Li W*, Wang Q*. Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nature Biomedical Engineering 2026.doi.org/10.1038/s41551-026-01720-9

  3. Li X#, Qiao Y#, Xu X#. Zhu J, Xie C, Lin S, Xu L*, and Yuan F*, 6′'-O-acetylsaikosaponin D targets STAT3-mediated transcriptional remodeling to induce ferroptosis and apoptosis. Phytomedicine2026, 157:158301.

  4. Zheng Z#, Yuan F#, Li J#, Zhu X, Jia R, Wei J, Jia F, Hou X, Zhang Z, Wang Y*, Ma Y*, Jia W*, Zhao L*. Gut microbiota-mediated bile acid metabolism regulates colorectal cancer liver metastasis by altering neutrophil recruitment. Cancer Research, 2025, CAN-24-4425.

  5. Zhang Y#, Song X#, Zhang N#, Li X, Wu F, Wei Y, Xu D, Xu L*, Yuan F*, Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. Advanced Science 2025, e04192.

  6. Li X#, Shen Y#, Zhang N#, Lu D#, Ding S, Wu F, Song X, Zhou X, Lin S, Xu H*, Wang Z*, Yuan F*. Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer.Genes & Diseases 2025, 13(2):101732.

  7. Wei Y, Hankey W, Xu D*, Yuan F*. Programmed cell death in cancer. MedComm 2025, 6(9):e70357.

  8. Wei Y, Mei Z, Xie C, Yuan F*, Xu D*. Mapping the application landscape of artificial intelligence in prostate cancer: a global bibliometric analysis. International Journal of Surgery 2025, 112(2):2988-3002.

  9. Zhou Q#, Wu F#, Chen Y, Fu J, Zhou L, Xu Y, He F*, Gong Z*, Yuan F*. Reynoutria multiflora (Thunb.) Moldenke and its ingredient suppress lethal prostate cancer growth by inducing CDC25B-CDK1 mediated cell cycle arrest. Bioorganic Chemistry 2024, 152:107731.

  10. Wang R, Wang C, Lu L, Yuan F*, He F*. Baicalin and Baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives. Pharmacological Research 2023, 199:107032.

  11. Chen Y#, Zhou Q#, Zhang H, Xu L,Lu L, Shu B*, Zhou L*, Yuan F*. QDT suppresses prostate cancer growth in lethal-stage prostate cancer models. Journal of Ethnopharmacology 2023, 308:116333.

  12. Zhou Q#, Chen Y#, Wang R, Jia F, He F, Yuan F*. Advances of CRISPR-Cas13 System in COVID-19 Diagnosis and Treatment. Genes & Diseases 2022, 10(6):2414-2424.

  13. Chen Y#, Zhou Q#, Hankey W, Fang X*, Yuan F*. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease2022, 13(7):632.

  14. Yuan F, Hankey W, Wagner EJ, Li W, Wang Q*. Alternative polyadenylation of mRNA and its role in cancer. Genes & Diseases 2021, 8(1): 61-72.

  15. Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong A, Huang J, Chen Z*, Wang Q*. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research 2019, 47(19):10104-10114.

  16. Yuan F, Xu C, Li G, Tong T*. Nucleolar TRF2 attenuated nucleolus stress-induced HCC cell-cycle arrest by altering rRNA synthesis. Cell Death & Disease 2018, 9(5):518.

  17. Yuan F, Li G, Tong T*. Nucleolar and coiled-body phosphoprotein 1 (NOLC1) regulates the nucleolar retention of TRF2. Cell Death Discovery 2017, 4 (3):17043.

  18. Yuan F, Zhang Y, Ma L, Cheng Q, Li G, Tong T*. Enhanced NOLC1 promotes cell senescence and represses HCC proliferation by disturbing the organization of nucleolus. Aging Cell 2017, 16(4):726-737.